Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Nov 13, 2024 · CIK: 1581178
Sentiment: neutral
Topics: sec-filing, 6-k, press-release
TL;DR
Eupraxia Pharma dropped a 6-K with a Nov 12 press release, check it out.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on November 13, 2024, reporting on events for the month of November 2024. The filing includes Exhibit 99.1, a press release dated November 12, 2024. The company is incorporated in Canada and its principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' activities and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not appear to contain significant new financial or operational information.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- November 12, 2024 (date) — Press Release Date
- November 13, 2024 (date) — Filing Date
- Victoria, British Columbia, Canada (location) — Principal Executive Office Location
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country, files or makes public with a stock exchange on which it has a listing, or distributes or makes public to its security holders.
What specific document is included as part of this 6-K filing?
Exhibit 99.1, a Press Release dated November 12, 2024, is included as part of this report.
What is Eupraxia Pharmaceuticals Inc.'s standard industrial classification?
Eupraxia Pharmaceuticals Inc.'s standard industrial classification is Pharmaceutical Preparations [2834].
What is the filing date of this Form 6-K?
This Form 6-K was filed on November 13, 2024.
Does Eupraxia Pharmaceuticals file under Form 20-F or Form 40-F for annual reports?
Eupraxia Pharmaceuticals Inc. files under Form 40-F for its annual reports, as indicated by the checkmark next to 'Form 40-F'.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-11-12 19:24:55
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 27KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001373.txt ( ) — 72KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: November 12, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer